



Board of Directors Report For the Financial Period January/March 2026 (Consolidated Statements)

We present the Board of Directors' report on the consolidated financial statements for the period from January 1, 2026, to March 31, 2026, for the Egyptian International Pharmaceutical Industries Company (EIPICO).

Company Overview:

Purpose: EIPICO engages in pharmaceuticals, medical products, cosmetics, chemicals, veterinary products, pesticides, dietary supplements, medical plants, special foods, glass ampoule manufacturing, and plastic pharmaceutical packaging. It operates within and beyond Egypt.

The duration of the company has been extended to twenty-five years, commencing from December 18, 2005, and ending on December 17, 2030, with the possibility of renewal for a similar period by a decision of the Extraordinary General Assembly.

The company is subject to Law No. 43 of 1974, as amended by Law No. 32 of 1977.

Key Data:

Authorized Capital: EGP 6,000,000,000

Paid-Up Capital: EGP 1,687,557,500

Issued Capital: EGP 1,687,557,500

Nominal Value per Share: EGP 10

Commercial Registry Number and Date: 11116, December 3, 1980



As we conclude the first quarter of 2026, we present the following consolidated significant achievements:

1. Net Sales (Revenue):

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Domestic Market Net Sales	1459.0	1431.62	27.38	1.91 %
Tender Sales Net Sales	276.72	127.58	149.14	116.90 %
Export Net Sales	781.42	730.84	50.58	6.92 %
Toll Sales to Others	15.69	9.85	5.84	59.29 %
Total Company Net Sales	2532.83	2299.89	232.94	10.13 %

Cost of Goods Sold:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cost of Goods Sold	1459.12	1248.80	210.32	16.84 %
Cost of Goods Sold to Net Sales	%57.6	%54.3	-	-

2. Production:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Production Value	2553	2455	98.0	4 %



3. Profitability:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Gross Profit	1074	1051	23	2%
Net Profit Before Tax	401	434	(33)	(8%)
Net Profit After Tax	284	319	(35)	(11%)

4. Assets under construction:

Category	During the Period (Million EGP)	December 31, 2024 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Assets under construction	3984	4901	(917)	(19%)

5. Cash Flows and Cash Balances:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cash Flows from Operations	(1052)	128	(1180.38)	(922.17%)
Cash Flows from Investing	(621)	(185)	(436.05)	(235.8%)
Cash Flows from Financing	630	342	288.19	84.27%
Net Cash Flow for the Period	(1043)	285	(1328.24)	(465.93%)
Exchange Rate Impact on Cash	(27)	(7)	(20.05)	(271.31%)
Cash Balance at the Beginning	1433	1295	138.04	(10.66%)

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cash Balance on June 30, 2024	370	1573	(1203.17)	(76.49%)

6. Capital:

Category	During the Period (Million EGP)	31/12/2025 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Capital	1,687.557	1,687.557	-	-

7. Treasury Shares:

Category	During the Period (Million EGP)	December 31, 2025 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Treasury Shares	0	0	0	0

8. Equity (Including Surplus of the Period):

Category	During the Period (Million EGP)	December 31, 2025 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Equity (Including Surplus)	5681	6532	(851)	(13%)

Accept our sincere regards and respect.



Chairman and Managing Director

Dr. Ahmed Kelani

